Drug Profile
Research programme: estrogen receptor alpha modulators - Shanghai ChemPartner/Shenogen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Shenogen Pharma
- Developer ShangPharma; Shenogen Pharma
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in China (Parenteral)
- 16 Mar 2011 Early research in Cancer in China (Parenteral)